uPAR Antibody (1065526) [Unconjugated]

uPAR was detected in immersion fixed MDA‑MB‑231 human breast cancer cell line (Positive) and absent in U266 human myeloma cell line (Negative) using Mouse Anti-Human uPAR Monoclonal Antibody (Catalog # MAB11694) at 8 µg/ml for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to the cytoplasm of MDA-MB-231 cells. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

• Reactivity: Hu
• Applications: ICC/IF
• Clone: 1065526
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

uPAR Antibody (1065526) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line, NS0-derived human uPAR
  Leu23-Arg303
  Accession # Q03405
• Specificity: Detects recombinant human Urokinase R protein in Direct ELISA.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from ascites

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry 3-25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Reconstitution Instructions: Reconstitute lyophilized material at 0.2 mg/ml in sterile PBS. For liquid material, refer to CoA for concentration.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for uPAR Antibody (1065526) [Unconjugated]

• CD87 antigen
• CD87
• Monocyte activation antigen Mo3
• plasminogen activator, urokinase receptor
• PLAUR
• uPAR
• U-PAR
• UPARurokinase plasminogen activator surface receptor
• u-plasminogen activator receptor form 2
• URKRMO3

Background

The urokinase-type Plasminogen Activator (uPA) is one of two activators that converts the extracellular zymogen plasminogen to plasmin, a serine protease that is involved in a variety of normal and pathological processes that require cell migration and/or tissue destruction. uPA is synthesized and released from cells as a single-chain (sc) pro-enzyme with limited enzymatic activity and is converted to an active two-chain (tc) disulfide-linked active enzyme by plasmin and other specific proteinases. Both the scuPA and tcuPA bind with high-affinity to the cell surface via the glycosyl phosphatidylinositol-linked receptor uPAR which serves to localize the uPA proteolytic activity. The enzymatic activity of scuPA has also been shown to be enhanced by binding to uPAR. Independent of their proteolytic activity, the uPA/uPAR interaction also initiates signal transduction responses resulting in activation of protein tyrosine kinases, gene expression, cell adhesion, and chemotaxis. uPAR can interact with integrins to suppress normal integrin adhesive function and promote adhesion to vitronectin through a high affinity vitronectin binding site on uPAR. uPAR cDNA encodes a 335 amino acid (aa) residue precursor protein with a 22 aa residue signal peptide, five potential N-linked glycosylation sites and a C-terminal GPI-anchor site. An alternate spliced variant of uPAR encoding a secreted soluble form of uPAR also exists. Human and mouse uPAR share approximately 60% aa sequence identity and the receptor-ligand interaction is strictly species-specific.

1. Dear, A.E. and R.L. Medcalf (1988) Eur. J. Biochemistry 252:185.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q03405()